MERCURYLAB.BO · BSE
Mercury Laboratories Limited
₹815.05
+0.62% (+₹5.05)
Prev. close
₹810
Volume
144
As of
BSE · may be slightly delayed · 16:00 IST
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Mercury Laboratories Limited
Mercury Laboratories Limited engages in manufacturing, selling, exporting, and dealing in various pharmaceutical drugs and medicines for mother and child healthcare in India and internationally. The company offers analgesic, anti-inflammatory, anti-pyretic, anthelmintic, antibiotic, anti-coagulant, anti-platelet, bleeding agent, anti-fungal, anti-hypertensive, anti-malarial, cardiovascular system, central nervous system, eye, gastro-intestinal system, hypoglycemic/anti-diabetic, multivitamin, protein supplement, respiratory system, anti-allergic, steroids, urinary system, uterine stimulant, and other drugs; and formulations, including tablets, oral liquids, injections, small volume parenterals, and eye/ear drops. It also provides antihypertensive, galactagogue, PCOS and uterine disorders, haemostat, digestive enzyme, utertonic, anti-fungal, constipation, vitamin K1, Nutritional Vitamin D, nausea vomiting in Pregnancy, nutrional supplement for gynec, pediatric, surgeon, and physician applications. The company export its products comprising anti-inflammatory, antimalarial, digestive, hypoglycemic, multivitamin, CNS, pain management, gynec, CVS, cough and cold, miscellaneous, and other formulations, as well as antibiotic, antifungal, and antiviral formulations to approximately 25 countries, including the Philippines, Myanmar, Sri Lanka, Vietnam, Cambodia, D.R. Congo, Ghana, Nigeria, Mozambique, Zambia, Kenya, lvory Coast, Mauritania, Burundi, Togo, Guatemala, Costa Rica, Peru, Ecuador, the United Kingdom, the United States, Moldova, and Jamaica. Mercury Laboratories Limited was founded in 1962 and is headquartered in Vadodara, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Rajendra Ramanlal Shah
Headquarters
Vadodara
Employees
510
Website
mercurylabs.comExchange
View on BSE ↗Key stats
Market cap
₹97.20 Cr
P/E ratio (TTM)
23.3
Dividend yield
0.43%
EPS (TTM)
₹34.72
Beta (1Y · daily vs NIFTY 50)
0.61
Beta (5Y · monthly vs NIFTY 50)
1.09
Shares float
1.66 L
EPS · quarter ended Jun 2026
₹2.48
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: Yahoo (no NSE corporate-actions ledger for this listing).
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹68.60 Cr | ₹57.92 Cr | ₹75.33 Cr | ₹75.56 Cr | ₹75.10 Cr | ₹75.94 Cr | |
| EBITDA | ₹10.47 Cr | ₹7.93 Cr | ₹9.98 Cr | ₹9.80 Cr | ₹7.75 Cr | ₹10.23 Cr |
| ₹5.34 Cr | ₹3.69 Cr | ₹5.58 Cr | ₹5.65 Cr | ₹3.14 Cr | ₹4.83 Cr | |
| Diluted EPS | ₹44.48 | ₹30.72 | ₹46.49 | ₹47.12 | ₹26.21 | ₹40.28 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹64.16 Cr | ₹67.96 Cr | ₹74.24 Cr | ₹79.08 Cr | |
| — | — | ₹5.83 Cr | ₹5.55 Cr | ₹5.45 Cr | ₹8.43 Cr | |
| Stockholders' equity | — | — | ₹45.63 Cr | ₹50.84 Cr | ₹53.57 Cr | ₹58.08 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹2.45 Cr | ₹8.23 Cr | ₹4.86 Cr | ₹4.24 Cr | |
| Investing cash flow | — | — | ₹-1.06 Cr | ₹-6.27 Cr | ₹-9.04 Cr | ₹-3.17 Cr |
| — | — | ₹-1.01 Cr | ₹-1.04 Cr | ₹-1.85 Cr | ₹2.91 Cr | |
| Capital expenditure | — | — | ₹-1.06 Cr | ₹-6.27 Cr | ₹-9.04 Cr | ₹-3.17 Cr |
| End cash position | — | — | ₹7.32 Cr | ₹8.23 Cr | ₹2.19 Cr | ₹6.18 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| Mercury Laboratories Limited | ₹98.04 Cr | ₹817 | 23.5 | 1.69 | 8.3% | 0.15 | +1.1% | -6.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 21
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.